Revance Therapeutics (RVNC) Tops Q1 EPS by 1c

Revance Therapeutics (NASDAQ: RVNC) reported Q1 EPS of ($1.08), $0.01 better than the analyst estimate of ($1.09). Revenue for the quarter came in at $13.3 million versus the consensus estimate of $10.98 million.

For earnings history and earnings-related data on Revance Therapeutics (RVNC) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• Ennis (EBF) Reports In-Line Q1 EPS
• Morgan Stanley Starts Adani Enterprises Ltd. (ADE:IN) at Overweight